Mga Batayang Estadistika
| LEI | 529900HH4WQT03IG1A12 |
| CIK | 1370053 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to AnaptysBio, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 6, 2025 |
As filed with the Securities and Exchange Commission on August 6, 2025 As filed with the Securities and Exchange Commission on August 6, 2025 Registration No. |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: August 6, 2025 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2025 OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-37985 ANAPTYSBIO, INC. (E |
|
| August 6, 2025 |
Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update •Announces positive data for rosnilimab, a pathogenic T cell depleter, through Week 38 from Phase 2b rheumatoid arthritis trial •Enrollment completed for rosnilimab Phase 2 ulcerative colitis trial; Top-line data through Week 12 on track for Q4 2025 •Ongoing Phase 1 trials in healthy volunteers for ANB033, a CD122 |
|
| August 6, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) AnaptysBio, Inc. |
|
| June 17, 2025 |
Amended and Restated 2017 Equity Incentive Plan anab-ar2017eipasadopted 1 ANAPTYSBIO, INC. AMENDED AND RESTATED 2017 EQUITY INCENTIVE PLAN (AS AMENDED AND RESTATED JUNE 17, 2025) 1. PURPOSE. The purpose of this Plan is to provide incentives to attract, retain and motivate eligible persons whose present and potential contributions are important to the success of the Company, and any Parents and Subsidiaries that exist now or in the future, by of |
|
| June 17, 2025 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: June 17, 2025 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 3, 2025 |
anaptyscorporatepresenta June 2025 Corporate Overview This presentation and any accompanying oral presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the timing of the release of data from the Company’s clinical trials, including rosnilimab’s Phase 2b clinical tri |
|
| June 3, 2025 |
Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA Best-in-disease profile with JAK-like efficacy and monthly (Q4W) dosing in both three-month placebo- controlled and six-month blinded treatment period Favorable safety and tolerability, particularly when compared to standard of care biologics or JAKs Max response rates have not yet been observed; strict continuation criteria at three months in this Phase 2b trial excluded many patients who either achieved or were trending toward LDA and ACR50 Durable responses for at least two months off drug, with potential for extended dosing intervals (e. |
|
| June 3, 2025 |
rosnilimabpd-1depleteran Rosnilimab: Updated Phase 2b Data in RA June 3, 2025 This presentation and any accompanying oral presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the timing of the release of data from the Company’s clinical trials, including rosnilimab |
|
| June 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: June 3, 2025 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2025 OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-37985 ANAPTYSBIO, INC. ( |
|
| May 5, 2025 |
vandalicenseagreement-re CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT ANAPTYSBIO, INC. |
|
| May 5, 2025 |
Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update •Announced rosnilimab, a depleter and agonist targeting PD-1+ T cells, achieved positive results in Phase 2b rheumatoid arthritis (RA) trial; to present updated clinical and translational data in the first week of June •Initial Phase 2 data for rosnilimab in ulcerative colitis (UC) on track for Q4 2025 •Ongoing Phase 1a trials in healthy volunteers for ANB033, a CD122 antagonist, and ANB101, a BDCA2 modulator •Authorized a $75 million Stock Repurchase Program in March 2025 and reiterating cash runway through year-end 2027 SAN DIEGO, May 5, 2025 — AnaptysBio, Inc. |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: May 5, 2025 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defini |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| March 24, 2025 |
Anaptys Announces Stock Repurchase Plan Anaptys Announces Stock Repurchase Plan SAN DIEGO, March 24, 2025 — AnaptysBio, Inc. |
|
| March 24, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: March 24, 2025 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-37985 ANAPTYSBIO, INC. (Exact n |
|
| February 27, 2025 |
Insider Trading Policy (as amended December 2, 2024) I. Purpose It is illegal for any employee, officer or director of AnaptysBio, Inc. (collectively with its subsidiaries, the “Company”), to trade in the securities of the Company while in the possession of material nonpublic information about the Company. It is also illegal for any employee, officer or director of the Company to give material non |
|
| February 27, 2025 |
Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update •Announced rosnilimab, a PD-1 depleter and agonist, achieved positive results from Phase 2b rheumatoid arthritis (RA) trial and highest-ever reported CDAI LDA response over 6 months •Full clinical and translational data for rosnilimab in RA in Q2 2025 •Top-line Phase 2 data for rosnilimab in ulcerati |
|
| February 27, 2025 |
Subsidiaries of the Registrant. EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT Name of Subsidiary Jurisdiction of Incorporation or Organization AnaptysBio Pty Ltd Australia |
|
| February 27, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: February 27, 2025 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| February 27, 2025 |
Amended and Restated Employment Agreement, effective April 2 ANAPTYSBIO, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is made effective from April 25, 2022 (the “Effective Date”) by and among ANAPTYSBIO, INC. (the “Company”) and Dennis Mulroy (“CFO”). The Company and CFO are hereinafter collectively referred to as the “Parties,” and individually referred to as a “Party.” This Agreement amen |
|
| February 19, 2025 |
February 2025 Corporate Overview This presentation and any accompanying oral presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the timing of the release of data from the Company’s clinical trials, including rosnilimab’s Phase 2b clinical trial in rheumatoid arth |
|
| February 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: February 19, 2025 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| February 18, 2025 |
JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) EXHIBIT 99.1 JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned |
|
| February 14, 2025 |
EXHIBIT 99.1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of Common Stock of AnaptysBio, Inc. Date: February 14, 2025 FRAZIER LIFE SCIENCES PUBLIC FUND, L.P. By: FHMLSP, L.P. |
|
| February 14, 2025 |
EXHIBIT 99.1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of Common Stock of AnaptysBio, Inc. Date: February 14, 2025 FRAZIER LIFE SCIENCES PUBLIC FUND, L.P. By: FHMLSP, L.P. |
|
| February 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: February 12, 2025 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| February 12, 2025 |
rosnilimab2-12x25pr Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months • Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS- 28 CRP across all rosnilimab doses vs. |
|
| February 12, 2025 |
Feb. 12, 2025 Rosnilimab: Phase 2b Top-line Data in RA This presentation and any accompanying oral presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the timing of the release of data from the Company’s clinical trials, including rosnilimab’s Phase 2b clinical tr |
|
| February 3, 2025 |
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist • Imsidolimab has successfully completed two global Phase 3 studies in Generalized Pustular Psoriasis • Vanda expects to immediately begin preparing BLA and MAA applications for the US and EU • Anaptys to receive $15 million from Vanda, comprised of a $10 million upfront payment and $5 million for existing drug supply • Anaptys to receive a 10% royalty on global net sales of imsidolimab WASHINGTON AND SAN DIEGO, Feb. |
|
| February 3, 2025 |
Regulation FD Disclosure, Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: January 31, 2025 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| December 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: December 11, 2024 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 15, 2024 |
As Filed Pursuant to Rule 424(b)(5) Registration No. 333-283001 PROSPECTUS SUPPLEMENT (To Prospectus Dated November 15, 2024) AnaptysBio, Inc. $100,000,000 Common Stock We have entered into a sales agreement, or the sales agreement, with TD Securities (USA) LLC, or TD Cowen, relating to the sale of shares of our common stock, $0.001 par value per share, offered by this prospectus supplement and |
|
| November 14, 2024 |
ANAB / AnaptysBio, Inc. / Deep Track Capital, LP Passive Investment SC 13G/A 1 deeptrack-anab093024a2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* ANAPTYSBIO, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 032724106 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriat |
|
| November 14, 2024 |
ANAB / AnaptysBio, Inc. / TANG CAPITAL MANAGEMENT LLC - AMENDMENT NO. 3 Passive Investment SC 13G/A 1 anab1015240sc13ga3.htm AMENDMENT NO. 3 Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* AnaptysBio, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 032724106 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the ap |
|
| November 13, 2024 |
ANAPTYSBIO, INC. 10770 Wateridge Circle, Suite 210 San Diego, CA 92121 ANAPTYSBIO, INC. 10770 Wateridge Circle, Suite 210 San Diego, CA 92121 November 13, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Lauren Hamill Re: AnaptysBio, Inc. Registration Statement on Form S-3 (File No. 333-283001) Requested Date: November 15, 2024 Requested Time: 4:00 PM Eastern Time Ladies |
|
| November 5, 2024 |
Exhibit 4.2 FORM OF DEBT SECURITY [Face of Security] ANAPTYSBIO, INC. [If applicable, insert—FOR PURPOSES OF THE ORIGINAL ISSUE DISCOUNT PROVISIONS OF THE INTERNAL REVENUE CODE OF 1986, THE ISSUE PRICE OF THIS SECURITY IS % OF ITS PRINCIPAL AMOUNT AT STATED MATURITY SET FORTH BELOW (ITS “PRINCIPAL AMOUNT”), THE AMOUNT OF ORIGINAL ISSUE DISCOUNT IS % OF ITS PRINCIPAL AMOUNT, THE YIELD TO MATURITY I |
|
| November 5, 2024 |
EXHIBIT 107 Calculation Of Filing Fee Tables Form S-3 (Form Type) AnaptysBio, Inc. |
|
| November 5, 2024 |
Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update •Top-line Phase 2b data anticipated for ANB032, our BTLA agonist, in atopic dermatitis (AD) in December 2024 •Top-line Phase 2b data anticipated for rosnilimab, our PD-1 agonist, in rheumatoid arthritis (RA) in February 2025 •Phase 1 trial initiated in healthy volunteers for ANB033, our anti-CD122 antagonist •Reiterating cash runway through year-end 2026 SAN DIEGO, Nov. |
|
| November 5, 2024 |
, 2024, by and between the Registrant and TD Securities (USA) LLC. ANAPTYSBIO, INC. COMMON STOCK SALES AGREEMENT November 5, 2024 TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New York 10022 Ladies and Gentlemen: AnaptysBio, Inc. (the “Company”), confirms its agreement (this “Agreement”) with TD Securities (USA) LLC (“TD Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time during the term of this Agreement, on th |
|
| November 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2024 OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-37985 ANAPTYSBIO, IN |
|
| November 5, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: November 5, 2024 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| November 5, 2024 |
Exhibit 4.3 ANAPTYSBIO, INC. And , as Trustee INDENTURE Dated as of , TABLE OF CONTENTS ARTICLE 1 - DEFINITIONS AND INCORPORATION BY REFERENCE 1.1. DEFINITIONS 1.2. OTHER DEFINITIONS 1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT 1.4. RULES OF CONSTRUCTION ARTICLE 2 - THE SECURITIES 2.1. ISSUABLE IN SERIES 2.2. ESTABLISHMENT OF TERMS OF SERIES OF SECURITIES 2.3. EXECUTION AND AUTHENTICATIO |
|
| November 5, 2024 |
As filed with the Securities and Exchange Commission on November 5, 2024 As filed with the Securities and Exchange Commission on November 5, 2024 Registration No. |
|
| August 16, 2024 |
ANAB / AnaptysBio, Inc. / EcoR1 Capital, LLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* AnaptysBio, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 032724106 (CUSIP Number) James J. Frolik, Esq. Anthony J. Caldwell, Esq. Shartsis Friese LLP 425 Market Street, 11th Floor San Francisco, CA 94105 (Name, Addr |
|
| August 14, 2024 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-261953 PROSPECTUS SUPPLEMENT (To prospectus dated January 11, 2022) 2,750,498 Shares Common Stock We are offering 2,750,498 shares of our common stock in this offering. Our common stock is listed on The Nasdaq Global Select Market under the symbol “ANAB.” On August 13, 2024, the last reported sale price of our common sto |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: August 13, 2024 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| August 14, 2024 |
Underwriting Agreement dated August 13, 2024 Exhibit 1.1 2,750,498 SHARES ANAPTYSBIO, INC. COMMON STOCK, PAR VALUE $0.001 PER SHARE UNDERWRITING AGREEMENT August 13, 2024 TD SECURITIES (USA) LLC LEERINK PARTNERS LLC As Representatives of the several Underwriters c/o TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 c/o Leerink Partners LLC 255 California Street, 5th Floor San Francisco, California 94111 Dear Sirs: 1. INTR |
|
| August 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2024 OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-37985 ANAPTYSBIO, INC. (E |
|
| August 5, 2024 |
Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update •Top-line data expected in December 2024 after having completed enrollment for Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist •Top-line data accelerated and now anticipated in Q1 2025 for Phase 2b trial to treat rheumatoid arthritis (RA) with rosnilimab, our PD-1 agonist •Top-line data now anticipated in Q1 2026 for Phase 2 trial to treat ulcerative colitis (UC) with rosnilimab •IND accepted by FDA for ANB033, our anti-CD122 antagonist; Phase 1 trial initiation anticipated in Q4 2024 SAN DIEGO, August 5, 2024 — AnaptysBio, Inc. |
|
| August 5, 2024 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT ANAPTYSBIO, INC. |
|
| August 5, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: August 5, 2024 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| August 5, 2024 |
As filed with the Securities and Exchange Commission on August 5, 2024 As filed with the Securities and Exchange Commission on August 5, 2024 Registration No. |
|
| August 5, 2024 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) AnaptysBio, Inc. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.001 par value per sh |
|
| June 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: June 12, 2024 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 12, 2024 |
anab-ar2017equityincenti 1 ANAPTYSBIO, INC. AMENDED AND RESTATED 2017 EQUITY INCENTIVE PLAN (AS AMENDED AND RESTATED June 12, 2024) 1. PURPOSE. The purpose of this Plan is to provide incentives to attract, retain and motivate eligible persons whose present and potential contributions are important to the success of the Company, and any Parents and Subsidiaries that exist now or in the future, by o |
|
| May 9, 2024 |
Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update •Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist; reiterating top-line data anticipated by year-end 2024 •Enrollment ongoing for global Phase 2b trial to treat rheumatoid arthritis (RA) and global Phase 2 trial to treat ulcerative colitis (UC) with rosnilim |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: May 9, 2024 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| May 9, 2024 |
1 AMENDMENT NO. 1 TO LICENSE AGREEMENT THIS AMENDMENT NO. 1 TO LICENSE AGREEMENT (this “Amendment”) dated as of the date of last signature, is entered into between ANAPTYSBIO, INC., a Delaware corporation (“AnaptysBio”), having a place of business at 10770 Wateridge Circle, Suite 210, San Diego, California 92121, and CENTESSA PHARMACEUTICALS (UK) LIMITED, a company incorporated in accordance with |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2024 OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-37985 ANAPTYSBIO, INC. ( |
|
| May 6, 2024 |
EX-99.A 2 d792368dex99a.htm EX-99.A EXHIBIT A AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of Common Stock of AnaptysBio, Inc. Date: May 6, 2024 FRAZIER LIFE SCIENCES PUBLIC FUND, L.P. By |
|
| May 6, 2024 |
ANAB / AnaptysBio, Inc. / Frazier Life Sciences Public Fund, L.P. - SC 13G Passive Investment SC 13G 1 d792368dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* AnaptysBio, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 032724106 (CUSIP Number) April 29, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| April 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defini |
|
| April 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| March 11, 2024 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) AnaptysBio, Inc. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.001 par value per sh |
|
| March 11, 2024 |
Amendment No. 5 to Tesaro AnaptysBio Collaboration CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT ANAPTYSBIO, INC. |
|
| March 11, 2024 |
Subsidiaries of the Registrant. EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT Name of Subsidiary Jurisdiction of Incorporation or Organization AnaptysBio Pty Ltd Australia |
|
| March 11, 2024 |
, dated November 24, 2023, by and between the Re CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT ANAPTYSBIO, INC. |
|
| March 11, 2024 |
ANAPTYSBIO, INC. COMPENSATION RECOVERY POLICY (Adopted September 15, 2023) The Board has determined that it is in the best interests of the Company and its stockholders to adopt this Policy enabling the Company to recover from specified current and former Company executives certain incentive-based compensation in the event of an accounting restatement resulting from material noncompliance with any |
|
| March 11, 2024 |
As filed with the Securities and Exchange Commission on March 11, 2024 As filed with the Securities and Exchange Commission on March 11, 2024 Registration No. |
|
| March 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: March 11, 2024 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| March 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-37985 ANAPTYSBIO, INC. (Exact n |
|
| March 11, 2024 |
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update •Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist, with top-line data anticipated by year-end 2024 •Enrollment ongoing for global Phase 2b trial to treat rheumatoid arthritis (RA) and global Phase 2 trial to treat ulcerative colitis (UC) with |
|
| February 14, 2024 |
ANAB / AnaptysBio, Inc. / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2024 |
ANAB / AnaptysBio, Inc. / Point72 Asset Management, L.P. - ANAPTYSBIO, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Anaptysbio, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 032724106 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w |
|
| February 14, 2024 |
ANAB / AnaptysBio, Inc. / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 2 Passive Investment SC 13G/A 1 z111240sc13ga2.htm AMENDMENT NO. 2 Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* AnaptysBio, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 032724106 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropr |
|
| February 13, 2024 |
ANAB / AnaptysBio, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: AnaptysBio Inc Title of Class of Securities: Common Stock CUSIP Number: 032724106 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: January 5, 2024 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| January 5, 2024 |
January 2024 Corporate Overview Nasdaq: ANAB This presentation and any accompanying oral presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the timing of the release of data from the Company’s clinical trials, including rosnilimab’s Phase 2b clinical trial in rhe |
|
| November 27, 2023 |
Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals •Anaptys licenses exclusive global development and commercialization rights to a potential best-in-class BDCA2 modulator portfolio •IND filing to support clinical development of ANB101 in autoimmune and inflammatory diseases expected in H2 2024 •Reiterating year-end 2023 cash and investments of $400 to $410 million and cash runway through year-end 2026 SAN DIEGO, Nov. |
|
| November 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: November 24, 2023 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 2, 2023 |
Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update •Initiated a global Phase 2b trial to treat rheumatoid arthritis (RA) with rosnilimab, our PD-1 agonist •Initiating in Q4 2023 a global Phase 2 trial to treat ulcerative colitis (UC) with rosnilimab •Announced positive top-line Phase 3 clinical trial results of imsidolimab (IL-36R) in generalized pustular psoriasis (GPP) •Reiterating cash runway through year-end 2026 and updating expected year-end 2023 cash and investments of $400 to $410 million SAN DIEGO, Nov. |
|
| November 2, 2023 |
ANAPTYSBIO, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is made effective as of August 4, 2023 (the “Effective Date”), by and among ANAPTYSBIO, INC. (the “Company”) and Daniel Faga (“Executive”). The Company and Executive are hereinafter collectively referred to as the “Parties,” and individually referred to as a “Party.” This Ag |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: November 2, 2023 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2023 OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-37985 ANAPTYSBIO, IN |
|
| October 25, 2023 | ||
| October 25, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: October 25, 2023 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| October 10, 2023 |
anaptysannouncespositive Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP) • 53. |
|
| October 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: October 9, 2023 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| October 2, 2023 |
ANAB / AnaptysBio Inc / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| September 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: September 14, 2023 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: August 7, 2023 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| August 7, 2023 |
Amended and Restated Certificate of Incorporation, as currently in effect. anaptysbioinc-derestated Delaware The First State Page 1 4062359 8100 Authentication: 203663607 SR# 20232896198 Date: 06-30-23 You may verify this certificate online at corp. |
|
| August 7, 2023 |
AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update •Completed enrollment of the GEMINI-1 Phase 3 trial for imsidolimab (IL-36R) in generalized pustular psoriasis (GPP) and anticipate top-line data in Q4 2023 •Initiating a global Phase 2b trial for rosnilimab, a PD-1 agonist antibody, in rheumatoid arthritis (RA) later in Q3 2023 and a second Phase 2 trial, in an indication yet to be announced, by year-end 2023 •Daniel Faga appointed to the permanent position of president and chief executive officer •Reiterating cash runway through year-end 2026 and updated expected year-end 2023 cash and investments of $380 – $395 million SAN DIEGO, August 7, 2023 — AnaptysBio, Inc. |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2023 OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-37985 ANAPTYSBIO, INC. (E |
|
| June 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: June 15, 2023 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 11, 2023 |
AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update •Initiated a global Phase 2b trial to treat atopic dermatitis with ANB032, a BTLA agonist •Hosting a virtual BTLA Agonist (ANB032) R&D Event on May 25, 2023 •Announced International Societies for Investigative Dermatology (ISID) Annual Meeting poster presentation for ANB032, a BTLA agonist, Phase 1 data •Initiating a global Phase 2b trial to treat rheumatoid arthritis in Q3 2023 and a second Phase 2 trial, in an indication to be announced, by year-end 2023 with rosnilimab, a PD-1 agonist •Reiterating cash runway through year-end 2026 with expected year-end 2023 cash and investments of $370 – $385 million SAN DIEGO, May 11, 2023 — AnaptysBio, Inc. |
|
| May 11, 2023 |
Amended and Restated Employment Agreement, effective loumeauthirdamemployment ANAPTYSBIO, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (this “Agreement”) is made effective from May 8, 2023 (the “Effective Date”) by and among AnaptysBio, Inc. (the “Company”) and Eric Loumeau (“Executive”). The Company and Executive are hereinafter collectively referred to as the “Parties,” and individually referred to |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: May 11, 2023 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2023 OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-37985 ANAPTYSBIO, INC. ( |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defini |
|
| April 27, 2023 |
DEFA14A 1 proxystatementadditionalma.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, f |
|
| April 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defini |
|
| April 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: April 1, 2023 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: March 1, 2023 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| March 1, 2023 |
AnaptysBio Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update •Initiating a global Phase 2b trial for rosnilimab (PD-1 agonist) to treat rheumatoid arthritis anticipated Q3 2023 •Initiating a global Phase 2b trial for ANB032 (BTLA agonist) to treat atopic dermatitis anticipated Q2 2023 •Initiating second Phase 2 trial for rosnilimab in an indication to be announced anticipated year-end 2023 •Filing IND for ANB033 (anti-CD122 antagonist) anticipated H1 2024 •Top-line data from the GEMINI-1 Phase 3 trial for imsidolimab (anti-IL-36R antagonist) to treat GPP anticipated Q4 2023 •Reiterating cash runway through year end 2026 SAN DIEGO, March 1, 2023 — AnaptysBio, Inc. |
|
| March 1, 2023 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) AnaptysBio, Inc. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.001 par value per sh |
|
| March 1, 2023 |
Subsidiaries of the Registrant. EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT Name of Subsidiary Jurisdiction of Incorporation or Organization AnaptysBio Pty Ltd Australia |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-37985 ANAPTYSBIO, INC. (Exact n |
|
| March 1, 2023 |
As filed with the Securities and Exchange Commission on March 1, 2023 As filed with the Securities and Exchange Commission on March 1, 2023 Registration No. |
|
| February 14, 2023 |
SC 13G/A 1 pt7213ga.htm SCHEDULE 13G/A, AMENDMENT #1 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* (Name of Issuer) AnaptysBio, Inc. (Title of Class |
|
| February 10, 2023 |
Second Amended and Restated Bylaws of the Registrant ANAPTYSBIO, INC., a Delaware Corporation SECOND AMENDED AND RESTATED BYLAWS As Amended and Restated on February 7, 2023 ANAPTYSBIO, INC., a Delaware Corporation SECOND AMENDED AND RESTATED BYLAWS TABLE OF CONTENTS Article I - STOCKHOLDERS Section 1.1: Annual Meetings Section 1.2: Special Meetings Section 1.3: Notice of Meetings Section 1.4: Adjournments Section 1.5: Quorum Section 1.6: Organizatio |
|
| February 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: February 7, 2023 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| February 10, 2023 |
ANAB / AnaptysBio Inc / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| February 9, 2023 |
ANAB / AnaptysBio Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: AnaptysBio Inc. Title of Class of Securities: Common Stock CUSIP Number: 032724106 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rul |
|
| February 9, 2023 |
ANAB / AnaptysBio Inc / FEDERATED HERMES, INC. Passive Investment SC 13G/A 1 form877.htm OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3*) ANAPTYSBIO, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 032724106 (CUSIP Number) January 31, 2023 (Date of Event Which Requir |
|
| February 1, 2023 |
ANAB / AnaptysBio Inc / FEDERATED HERMES, INC. Passive Investment SC 13G/A 1 form815.htm OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2*) ANAPTYSBIO, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 032724106 (CUSIP Number) December 31, 2022 (Date of Event Which Requi |
|
| January 13, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: January 13, 2023 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| January 13, 2023 |
AnaptysBio Announces Stock Repurchase Plan AnaptysBio Announces Stock Repurchase Plan SAN DIEGO, Jan. 13, 2023 — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the Company may repurchase up to $50,000,000 of the Company’s outstanding common stock, par value $0.001 |
|
| January 5, 2023 |
AnaptysBio Announces Portfolio Update Across Best-in-Class Immune Cell Modulating Antibodies AnaptysBio Announces Portfolio Update Across Best-in-Class Immune Cell Modulating Antibodies ?Advancing rosnilimab, its PD-1 agonist, into a global Phase 2b trial to treat rheumatoid arthritis with study initiation in Q3 2023 ?Advancing ANB032, its BTLA agonist, into a global Phase 2b trial to treat atopic dermatitis with study initiation in Q2 2023 ?Advancing rosnilimab into a second Phase 2 tria |
|
| January 5, 2023 |
Corporate Overview January 2022 Nasdaq: ANAB 2 This presentation and any accompanying oral presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the timing of initiation of the Company?s clinical trials, including rosnilimab?s clinical trials in rheumatoid arthritis |
|
| January 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: January 5, 2023 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| November 8, 2022 |
Sales Agreement, dated November 8, 2022, by and between the Registrant and Cowen and Company, LLC Exhibit 10.24 ANAPTYSBIO, INC. $150,000,000 COMMON STOCK SALES AGREEMENT November 8, 2022 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: AnaptysBio, Inc. (the ?Company?), confirms its agreement (this ?Agreement?) with Cowen and Company, LLC (?Cowen?), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time during the term of this |
|
| November 8, 2022 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMEMNT, MARKED BY [***], HAS BEEN OMITTED BECAUSE THE INFORMATION IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| November 8, 2022 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-261953 PROSPECTUS SUPPLEMENT (To Prospectus Dated January 11, 2022) AnaptysBio, Inc. $150,000,000 Common Stock We have entered into a sales agreement with Cowen and Company, LLC, or Cowen, relating to the sale of shares of our common stock, $0.001 par value per share, offered by this prospectus supplement and the accompanying base prospectus. I |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: November 8, 2022 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2022 OR ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-37985 ANAPTYSBIO, IN |
|
| November 8, 2022 |
Corporate Overview November 2022 Nasdaq: ANAB 2 This presentation and any accompanying oral presentation contain ?forward?looking? statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the timing of the release of data from our clinical trials, including imsidolimab?s Phase 3 trial in GPP and rosnilimab |
|
| November 8, 2022 |
AnaptysBio Announces Third Quarter 2022 Financial Results and Provides Pipeline Update AnaptysBio Announces Third Quarter 2022 Financial Results and Provides Pipeline Update ?Anticipate Rosnilimab, our anti-PD-1 agonist antibody, top-line data in the ongoing AZURE Phase 2 trial in moderate-to-severe alopecia areata in Q1 2023 ?Anticipate ANB032, our anti-BTLA agonist antibody, U. |
|
| September 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: September 9, 2022 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| September 12, 2022 |
Corporate Overview September 2022 Nasdaq: ANAB 2 This presentation and any accompanying oral presentation contain ?forward?looking? statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the timing of the release of data from our clinical trials, including imsidolimab?s Phase 3 trial in GPP and rosnilima |
|
| September 9, 2022 |
ANAB / AnaptysBio Inc / Point72 Asset Management, L.P. - SCHEDULE 13G Passive Investment 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. )* (Name of Issuer) AnaptysBio, Inc. (Title of Class of Securities) Common Stock, $0.001 Par Value Per Sha |
|
| September 9, 2022 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessi |
|
| August 31, 2022 |
AnaptysBio Reports HARP Phase 2 Top-Line Data of Imsidolimab in Moderate-to-Severe Hidradenitis Suppurativa ?Imsidolimab (anti-IL-36 receptor antagonist) did not demonstrate improvement over placebo in the primary endpoint and key secondary endpoints ?Imsidolimab was safe and well tolerated with no imsidolimab-related serious or severe adverse events reported ?Company to discontinue imsidolimab cl |
|
| August 31, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: August 31, 2022 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| August 15, 2022 |
ANAB / AnaptysBio Inc / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2022 OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-37985 ANAPTYSBIO, INC. (E |
|
| August 8, 2022 |
AnaptysBio Announces Second Quarter 2022 Financial Results and Provides Pipeline Update AnaptysBio Announces Second Quarter 2022 Financial Results and Provides Pipeline Update ?Top-line data from the ongoing imsidolimab (anti-IL-36R Ab) HARP Phase 2 trial in moderate-to-severe hidradenitis suppurativa is anticipated in Q3 2022 ?Top-line data from the ongoing rosnilimab (anti-PD-1 agonist Ab) AZURE Phase 2 trial in moderate-to-severe alopecia areata is anticipated in Q1 2023 SAN DIEGO, August 8, 2022 - AnaptysBio, Inc. |
|
| August 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: August 8, 2022 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| June 24, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: June 23, 2022 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 10, 2022 |
ANAB / AnaptysBio Inc / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ?.11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1*) ANAPTYBIO, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 032724106 (CUSIP Number) April 30, 2022 (Date of Event Which Requires Filing of this Statemen |
|
| May 4, 2022 |
Employment Agreement, effective March 21, 2022, by and between Registrant and Daniel Faga |
|
| May 4, 2022 |
, 2022, by and between Registrant and Hamza Suria CONSULTING AGREEMENT This Consulting Agreement (?Agreement?) is effective as of March 21, 2022 (the ?Effective Date?), between AnaptysBio, Inc. |
|
| May 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2022 OR ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-37985 ANAPTYSBIO, INC. ( |
|
| May 4, 2022 |
Separation Agreement effective March 20, 2022, by and between Registrant and Hamza Suria March 17, 2022 VIA E-MAIL Hamza Suria [email protected] Re: Terms of Separation Dear Hamza: This letter confirms the agreement (?Agreement?) between you and AnaptysBio, Inc. (the ?Company?) concerning the terms of your separation and offers you the Separation Compensation we discussed in exchange for a general release of claims and covenant not to sue. 1. Separation Date: March 20, 2022 is your |
|
| May 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: May 4, 2022 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| May 4, 2022 |
AnaptysBio Announces First Quarter 2022 Financial Results and Provides Pipeline Update AnaptysBio Announces First Quarter 2022 Financial Results and Provides Pipeline Update ?Top-line data from the ongoing imsidolimab (anti-IL-36R Ab) HARP Phase 2 trial in moderate-to-severe hidradenitis suppurativa is anticipated in Q3 2022 ?Top-line data from the ongoing imsidolimab GEMINI-1 Phase 3 trial in GPP is anticipated in Q4 2023 ?Top-line data from the ongoing rosnilimab (anti-PD-1 agonist Ab) AZURE Phase 2 trial in moderate-to-severe alopecia areata is anticipated in H1 2023 ?Ended Q1 2022 with approximately $596. |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defini |
|
| April 29, 2022 |
ANAPTYSBIO, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this ?Agreement?) is made effective from July 15, 2020 (the ?Effective Date?) by and among ANAPTYSBIO, INC. (the ?Company?) and Dennis Mulroy (?CFO?). The Company and CFO are hereinafter collectively referred to as the ?Parties,? and individually referred to as a ?Party.? This Agreement amend |
|
| April 29, 2022 |
ANAPTYSBIO, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this ?Agreement?) is made effective from April 25, 2022 (the ?Effective Date?) by and among ANAPTYSBIO, INC. (the ?Company?) and Paul Lizzul, MD (?CMO?). The Company and CMO are hereinafter collectively referred to as the ?Parties,? and individually referred to as a ?Party.? This Agreement am |
|
| April 29, 2022 |
ANAPTYSBIO, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (this ?Agreement?) is made effective from April 25, 2022 (the ?Effective Date?) by and among AnaptysBio, Inc. (the ?Company?) and Eric Loumeau (?Executive?). The Company and Executive are hereinafter collectively referred to as the ?Parties,? and individually referred to as a ?Party.? This Agr |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Ru |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: April 25, 2022 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| April 27, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: April 27, 2022 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| April 27, 2022 |
AnaptysBio Announces Positive ANB032 (anti-BTLA agonist) Top-Line Phase 1 Data and Provides Pipeline Updates ?ANB032, our wholly owned anti-BTLA agonist antibody, demonstrated favorable safety, tolerability and a rapid and sustained pharmacokinetic and pharmacodynamic profile that supports advancement of ANB032 into subsequent patient trials ?ANB032 IND filing in an initial proof-of-concept Phase 2 trial is anticipated in the second half of 2022 ?Imsidolimab (anti-IL-36R Ab) top-line data from the Phase 2 trial in moderate-to-severe hidradenitis suppurativa is anticipated in the third quarter of 2022 SAN DIEGO, April 27, 2022 - AnaptysBio, Inc. |
|
| March 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: March 20, 2022 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| March 14, 2022 |
AnaptysBio Reports Imsidolimab ACORN Phase 2 Clinical Trial Data in Moderate-to-Severe Acne AnaptysBio Reports Imsidolimab ACORN Phase 2 Clinical Trial Data in Moderate-to-Severe Acne ?Imsidolimab (anti-IL-36R Ab) treatment did not demonstrate improvement over placebo in top-line primary or secondary endpoints ?AnaptysBio to discontinue imsidolimab clinical development in acne ?Imsidolimab was generally safe, well tolerated and no imsidolimab-related serious or severe adverse events were |
|
| March 14, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: March 14, 2022 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| March 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-37985 ANAPTYSBIO, INC. (Exact n |
|
| March 7, 2022 |
Amendment No. 4 to Tesaro AnaptysBio Collaboration AMENDMENT NO. 4 TO COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT This Amendment No. 4 to the Collaboration and Exclusive License Agreement (this ?Amendment?) effective as of October 21, 2021 (the ?Amendment Date?), is entered into by and between (i) AnaptysBio, Inc., a Delaware corporation, having a place of business at 10770 Wateridge Circle, Suite 210, San Diego, California 92121 (?AnaptysBio?), |
|
| March 7, 2022 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) AnaptysBio, Inc. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.001 par value per sh |
|
| March 7, 2022 |
As filed with the Securities and Exchange Commission on March 7, 2022 As filed with the Securities and Exchange Commission on March 7, 2022 Registration No. |
|
| March 7, 2022 |
AnaptysBio Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Pipeline Update ?Imsidolimab GPP GALLOP Phase 2 16-week data presented at 2021 EADV Congress and Phase 3 GPP GEMINI-1 trial initiated ?Top-line data anticipated from ongoing imsidolimab ACORN Phase 2 trial in moderate-to-severe acne in H1 2022 and HARP Phase 2 trial in moderate-to-severe hidradenitis suppurativa |
|
| March 7, 2022 |
Subsidiaries of the Registrant. EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT Name of Subsidiary Jurisdiction of Incorporation or Organization AnaptysBio Pty Ltd Australia |
|
| March 7, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: March 7, 2022 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| February 15, 2022 |
ANAB / AnaptysBio Inc / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* AnaptysBio, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 032724 106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| February 15, 2022 |
EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 14, 2022 PERCEPTIVE ADVISORS LLC |
|
| February 14, 2022 |
ANAB / AnaptysBio Inc / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. *) ANAPTYBIO, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 032724106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statem |
|
| February 14, 2022 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessi |
|
| February 14, 2022 |
240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* (Name of Issuer) Anaptysbio, Inc. (Title of Class of Securities) Common Stock, $0.001 Par Value Per Sh |
|
| February 9, 2022 |
ANAB / AnaptysBio Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0262-anaptysbioinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: AnaptysBio Inc. Title of Class of Securities: Common Stock CUSIP Number: 032724106 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the r |
|
| January 7, 2022 |
ANAPTYSBIO, INC. 10770 Wateridge Circle, Suite 210 San Diego, CA 92121 January 7, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Michael Davis Re: AnaptysBio, Inc. Registration Statement on Form S-3 (File No. 333-261953) filed December 30, 2021. Requested Date: January 11, 2022 Requested Time: 4:00 |
|
| December 30, 2021 |
As filed with the Securities and Exchange Commission on December 30, 2021 Table of Contents As filed with the Securities and Exchange Commission on December 30, 2021 Registration No. |
|
| December 30, 2021 |
Open Market Sale AgreementSM, dated December 30, 2021, between the Registrant and Jefferies LLC EX-1.2 2 d282430dex12.htm EX-1.2 Exhibit 1.2 OPEN MARKET SALE AGREEMENTSM December 30, 2021 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: AnaptysBio, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), sha |
|
| December 30, 2021 |
Exhibit 4.3 ANAPTYSBIO, INC. And , as Trustee INDENTURE Dated as of , TABLE OF CONTENTS ARTICLE 1 - DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1. DEFINITIONS 1 1.2. OTHER DEFINITIONS 4 1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT 5 1.4. RULES OF CONSTRUCTION 6 ARTICLE 2 - THE SECURITIES 6 2.1. ISSUABLE IN SERIES 6 2.2. ESTABLISHMENT OF TERMS OF SERIES OF SECURITIES 6 2.3. EXECUTION A |
|
| December 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: December 1, 2021 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| December 1, 2021 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE THE INFORMATION IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
|
| November 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: November 26, 2021 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 15, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: November 15, 2021 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 15, 2021 |
AnaptysBio Announces Positive Rosnilimab Healthy Volunteer Phase 1 Top-Line Data AnaptysBio Announces Positive Rosnilimab Healthy Volunteer Phase 1 Top-Line Data ?Rosnilimab, AnaptysBio?s wholly-owned anti-PD-1 agonist antibody, demonstrated favorable safety and tolerability in single and multiple ascending dose healthy volunteer cohorts ?Robust pharmacokinetic profile, in conjunction with rapid and sustained PD-1 receptor occupancy ?Pharmacodynamic activity resulted in dose-d |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2021 OR ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-37985 ANAPTYSBIO, IN |
|
| November 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: November 4, 2021 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| November 4, 2021 |
AnaptysBio Announces Third Quarter 2021 Financial Results and Provides Pipeline Updates AnaptysBio Announces Third Quarter 2021 Financial Results and Provides Pipeline Updates ?Imsidolimab GPP GALLOP Phase 2 16-week data presented at 2021 EADV Congress and GEMINI-1 Phase 3 trial initiated subsequent to FDA end-of-Phase 2 meeting ?Top-line data from ongoing imsidolimab ACORN Phase 2 trial in moderate-to-severe acne anticipated in H1 2022 and HARP Phase 2 trial in moderate-to-severe hi |
|
| October 25, 2021 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: October 25, 2021 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| October 4, 2021 |
AnaptysBio Presents Updated Data From Imsidolimab Phase 2 GALLOP Trial in Generalized Pustular Psoriasis ?Imsidolimab demonstrated rapid and sustained efficacy with 6 of 8 (75%) generalized pustular psoriasis (GPP) patients achieving the primary endpoint at week 4 and week 16 ?Early reduction of erythema with pustules by 60% at week 1 improved to 94% reduction at week 4 and 98% reduction at week 1 |
|
| October 4, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: October 4, 2021 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| August 9, 2021 |
AnaptysBio Announces Second Quarter 2021 Financial Results and Provides Pipeline Updates AnaptysBio Announces Second Quarter 2021 Financial Results and Provides Pipeline Updates ?Imsidolimab GPP GEMINI-1 Phase 3 trial anticipated to initiate in Q3 2021 following recent FDA end-of-Phase 2 Meeting ?Imsidolimab GALLOP GPP Phase 2 trial 16-week data to be orally presented at the EADV Congress on October 2nd, 2021 ?Imsidolimab Phase 2 trials ongoing in acne, hidradenitis suppurativa, EGFR- |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2021 OR ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-37985 ANAPTYSBIO, INC. (E |
|
| August 9, 2021 |
First Amendment to Lease Agreement FIRST AMENDMENT TO LEASE AGREEMENT This FIRST AMENDMENT TO LEASE AGREEMENT (?Amendment?) is effective as of April 5, 2021 (?Amendment Effective Date?), by and between WATERIDGE PROPERTY OWNER, LP, a Delaware limited partnership (?Landlord?), and ANAPTYSBIO, INC. |
|
| August 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: August 9, 2021 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| June 17, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: June 17, 2021 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 3, 2021 |
EX-99.1 2 a632021presentation.htm ANAPTYSBIO PRESENTATION |
|
| June 3, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: June 3, 2021 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| May 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* AnaptysBio, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 032724106 (CUSIP Number) James J. Frolik, Esq. Anthony J. Caldwell, Esq. Shartsis Friese LLP One Maritime Plaza, 18th Floor San Francisco, CA 94111 (Name, Add |
|
| May 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: May 4, 2021 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 4, 2021 |
AnaptysBio Announces First Quarter 2021 Financial Results and Provides Pipeline Updates AnaptysBio Announces First Quarter 2021 Financial Results and Provides Pipeline Updates ?Imsidolimab Phase 3 GPP trial anticipated to commence in mid-2021 following FDA end-of-Phase 2 meeting held during Q2 2021 ?JEMPERLI (dostarlimab), our PD-1 antagonist antibody partnered with GlaxoSmithKline (GSK), was approved for endometrial cancer in the US and EU during Q2 2021, earning $30 million in cash |
|
| May 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2021 OR ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-37985 ANAPTYSBIO, INC. ( |
|
| April 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Ru |
|
| April 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| April 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* AnaptysBio, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 032724106 (CUSIP Number) James J. Frolik, Esq. Anthony J. Caldwell, Esq. Shartsis Friese LLP One Maritime Plaza, 18th Floor San Francisco, CA 94111 (Name, Add |
|
| April 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: April 8, 2021 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| March 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* AnaptysBio, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 032724106 (CUSIP Number) James J. Frolik, Esq. Anthony J. Caldwell, Esq. Shartsis Friese LLP One Maritime Plaza, 18th Floor San Francisco, CA 94111 (Name, Addr |
|
| March 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* AnaptysBio, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 032724106 (CUSIP Number) James J. Frolik, Esq. Anthony J. Caldwell, Esq. Shartsis Friese LLP One Maritime Plaza, 18th Floor San Francisco, CA 94111 (Name, Addr |
|
| March 8, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: March 8, 2021 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| March 8, 2021 |
AnaptysBio Reports Imsidolimab POPLAR Phase 2 Clinical Trial in Moderate-to-Severe Palmoplantar Pustulosis (PPP) Did Not Meet Primary Endpoint ?Imsidolimab treatment did not demonstrate statistically significant improvement over placebo in PPPASI change from baseline at week 16 primary endpoint ?Imsidolimab was generally well tolerated and no serious or severe adverse events were reported in the drug arm of the trial ?AnaptysBio does not currently plan to conduct further clinical development in PPP ?Advancement of imsidolimab to continue across 5 other distinct indications, including anticipated advancement into Phase 3 trial in generalized pustular psoriasis (GPP) in mid-2021 SAN DIEGO, March 8th, 2021 ? AnaptysBio, Inc. |
|
| February 25, 2021 |
Amendment No. 3 to the Collaboration and Exclusive License Agreement CERTAIN CONFIDENTIAL INFORMATION MARKED [***] HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
|
| February 25, 2021 |
As filed with the Securities and Exchange Commission on February 25, 2021 Registration No. |
|
| February 25, 2021 |
Confidential Settlement and Modification Agreement dated as of October 23, 2020 CERTAIN CONFIDENTIAL INFORMATION MARKED [***] HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
|
| February 25, 2021 |
TERMINATION OF SUBLEASE (Early Termination) THIS TERMINATION OF SUBLEASE (this "Agreement") is dated as of November 11, 2020, between TREX ENTERPRISES CORPORATION, a California corporation ("Sublessor"), and ANAPTYSBIO, INC. |
|
| February 25, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: February 25, 2021 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| February 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-37985 ANAPTYSBIO, INC. (Exact n |
|
| February 25, 2021 |
Subsidiaries of the Registrant. EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT Name of Subsidiary Jurisdiction of Incorporation or Organization AnaptysBio Pty Ltd Australia |
|
| February 25, 2021 |
AnaptysBio Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Pipeline Updates ?Positive topline data from GALLOP Phase 2 clinical trial of imsidolimab in moderate to severe generalized pustular psoriasis (GPP) announced in October 2020, with Phase 3 trial initiation anticipated in mid-2021 ?Topline data from POPLAR Phase 2 imsidolimab clinical trial in palmoplantar pustulo |
|
| February 16, 2021 |
Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 AnaptysBio, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 032724106 (CUSIP Number) December 31, 2020 |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: AnaptysBio Inc. Title of Class of Securities: Common Stock CUSIP Number: 032724106 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rul |
|
| February 8, 2021 |
SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* AnaptysBio, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 032724 106 (CUSIP Number) January 28, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| January 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: January 18, 2021 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| January 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) AnaptysBio, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 032724106 (CUSIP Number) January 4, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| January 13, 2021 |
240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.)* (Name of Issuer) Anaptysbio, Inc. (Title of Class of Securities) Common Stock, $0.001 Par Value (CUSIP N |
|
| January 13, 2021 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessi |
|
| January 11, 2021 | ||
| January 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: January 11, 2021 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 18, 2020 |
Amendment No. 3 to Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4)* AnaptysBio, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 032724106 (CUSIP Number) Steve R. Bailey Frazier Healthcare Partners 601 Union Street, Suite 3200 Seattle, WA 98101 |
|
| November 17, 2020 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: November 11, 2020 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 4, 2020 |
Employment Agreement, effective July 15, 2020, by and between Registrant and Dennis Mulroy ANAPTYSBIO, INC. EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”) is made effective from July 15, 2020 (the “Effective Date”) by and among ANAPTYSBIO, INC. (the “Company”) and Dennis Mulroy (“CFO”). The Company and CFO are hereinafter collectively referred to as the “Parties,” and individually referred to as a “Party.” RECITAL The Company desires to employ CFO, and CFO is willing |
|
| November 4, 2020 |
Employment Agreement, effective July 31, 2020, by and between Registrant and Paul Lizzul ANAPTYSBIO, INC. EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”) is made effective from July 31, 2020 (the “Effective Date”) by and among ANAPTYSBIO, INC. (the “Company”) and Paul Lizzul, MD (“CMO”). The Company and CMO are hereinafter collectively referred to as the “Parties,” and individually referred to as a “Party.” RECITAL The Company desires to employ CMO, and CMO is willin |
|
| November 4, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: November 4, 2020 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2020 OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-37985 ANAPTYSBIO, IN |
|
| November 4, 2020 |
AnaptysBio Announces Third Quarter 2020 Financial Results and Provides Pipeline Updates AnaptysBio Announces Third Quarter 2020 Financial Results and Provides Pipeline Updates •Positive topline data from GALLOP Phase 2 clinical trial of imsidolimab in moderate to severe Generalized Pustular Psoriasis (GPP) announced in October 2020 •FDA end-of-Phase 2 meeting anticipated in Q4 2020 to outline registration path of imsidolimab for the treatment of GPP, in accordance with the orphan dru |
|
| November 4, 2020 |
ANAPTYSBIO, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (this “Agreement”) is made effective from July 15, 2020 (the “Effective Date”) by and among AnaptysBio, Inc. (the “Company”) and Eric Loumeau (“Executive”). The Company and Executive are hereinafter collectively referred to as the “Parties,” and individually referred to as a “Party.” This Agre |
|
| October 26, 2020 |
Entry into a Material Definitive Agreement - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: October 23, 2020 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| October 13, 2020 |
EX-99 8 gallopgpppressrelease1.htm EX-99 AnaptysBio Reports Positive Topline Data from GALLOP Phase 2 Clinical Trial of Imsidolimab in Moderate-to-Severe Generalized Pustular Psoriasis (GPP) •6 of 8 patients achieved primary endpoint of improvement in the clinical global impression scale (CGI) on Day 29, with rapid reduction of skin pustules by 60% on Day 8 and 94% clearance on Day 29 •FDA end-of- |
|
| October 13, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: October 13, 2020 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 20, 2020 |
Termination of a Material Definitive Agreement - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 20, 2020 ANAPTYSBIO, INC. |
|
| August 10, 2020 |
AnaptysBio Announces Second Quarter 2020 Financial Results and Provides Pipeline Updates AnaptysBio Announces Second Quarter 2020 Financial Results and Provides Pipeline Updates •Interim 8-Week Top-Line Data From Etokimab ECLIPSE Phase 2 Trial in Chronic Rhinosinusitis with Nasal Polyps Did Not Demonstrate Statistical Significance For Either Q4W or Q8W Versus Placebo; Company Plans To Assess Path Forward for Etokimab After Complete 16-Week Trial Data by year-end 2020 •Following Orphan |
|
| August 10, 2020 |
EX-99.2 3 etokimabcrswnpiapr.htm EXHIBIT 99.2 AnaptysBio Reports Top-Line Data from Interim Analysis of ECLIPSE Phase 2 Clinical Trial of Etokimab in Chronic Rhinosinusitis with Nasal Polyps –Etokimab q4w and q8w treatment arms failed to achieve NPS and SNOT-22 statistical significance over placebo at this week 8 interim analysis –Secondary analyses demonstrated NPS and blood eosinophil level impr |
|
| August 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: August 10, 2020 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| August 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2020 OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-37985 ANAPTYSBIO, INC. (E |
|
| July 31, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: July 20, 2020 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| July 31, 2020 |
AnaptysBio Appoints Dr. Paul F. Lizzul As Chief Medical Officer Dermatology Physician-Scientist To Lead Wholly-Owned Pipeline Advancement SAN DIEGO, July 31st, 2020 - AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, t |
|
| July 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: July 13, 2020 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| July 15, 2020 |
AnaptysBio Expands Executive Leadership Team Appoints Dennis Mulroy as Chief Financial Officer and Eric Loumeau as Chief Operating Officer SAN DIEGO, July 15, 2020 - AnaptysBio, Inc. |
|
| June 19, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: June 19, 2020 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| May 6, 2020 |
LEASE AGREEMENT BETWEEN WATERIDGE PROPERTY OWNER, LP, a Delaware limited partnership (LANDLORD) AND ANAPTYSBIO, INC. |
|
| May 6, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: May 6, 2020 (Date of earliest event reported) ANAPTYSBIO, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37985 20-3828755 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
